Shots:

• The company presented new analysis data from the P-III EXPLORER-HCM trial assessing mavacamten in patients with oHCM that tested the impact of the therapy on patients’ health status i.e symptoms- function- and QoL
• The company unveils the interim results from MAVA-LTE- 5yrs. extension study of the EXPLORER-HCM. The study demonstrated improvement in LVOT gradients- diastolic function- NT-proBNP- and symptoms and was well tolerated
• The company also presented real-world data analysis measuring the clinical & economic burden of oHCM in the US. Mavacamten is an oral- allosteric modulator of cardiac myosin for patients with oHCM

­ Ref: PRNewswire | Image: BMS